Fribrinolysis kinetics and its application

Abstract

A new, convenient, and rapid method for kinetic measurement of human fibrinolysis was established. The alteration of absorbance (A) in the process of blood coagulation and lyses was automatically scanned and recorded using a UV2000 spectrophotometer connected to a computer. The parameters of human fibrinolysis kinetics were established. Urokinase at 20 U/mL was the optimal concentration used. There was significant difference in fibrinolysis kinetics and plasma plasminogen concentration between 22 normal subjects and 27 patients with acute myeloblastic leukemia (P<0.05 and <0.01 respectively). The coefficience of variation was (5.24±1.51)%. This method could also be used to measure the plasma fibrinogen concentration at the same time. It was concluded that this method was stable and was capable of providing dynamic, direct experimental data and multiparemeters for clinicians. It was also valuable in evaluating the anti-and pro-fibrinolytic capcity of patients’ plasmas, allowing for monitoring of therapy, choice of drugs and adjustment of drug concentrations.

Keywords

fibrinolysis / kinetic measurement / prothrombotic state

References

[1] WeiW. N., YangR., YanY., et al.. New kinetic measurement for thrombin generation and its clinical significance. J Clin Hematol (Chinese), 2002, 15(3): 120-122

[2] ZhongR., HuangR., SongS.. Experimental study of tissue factor pathway inhibitor-2 expression inhibiting the invasive potential of human ovarian tumor cells. Tumor (Chinese), 2004, 24(5): 444-447

[3] Downey C, Fischer T, Hargreavers D et al. The rebustness and reproducibility of APTT Waveform analysis in relation to reagent and batch variatial. XVIIth Congress of the Interational Society on Thrombosis and Haemostasis-Washington. 1994.

[4] Toh C H, Ticknor L O, Patonet R et al. APTT waveform analysis of lipoprotein-complexed C-reactive protein formation and its prediction of morality through the presence of overt/ono-overt DIC. XVIIIth congress of the international Society on Thrombosis and Haemostasis-Paris. 2001, abstr.P2583.

[5] XiM.. Evaluation of the fibrinogen molecular reactivity in patients with ischaemic cardiocerebrovascular disease. Chin J Hemato(Chinese), 1996, 17(3): 135-1376

[6] WeiW. N., YangR., YangY.. The variation of fibrinogen kinetics in thrombolytic therapy. J Clin Hematol (Chinese), 2001, 14(3): 115-116

[7] WeiW. N., YangR., YangY.. The Significance of variations in fibrin monomer polymerization function of patients with disseminated intravascular coagulation. Clin J Emer Med (Chinese), 2001, 10(5): 338-339

[8] Fukao H, Ueshhima S, Okada K, et al. The hyperthermic efferts on fibrinolytic factor and viabilities in carcinoma cell lines. XVIIIth congress of the international Society on Thrombosis and Haemostasis-Paris. 2001, abstr.CD3573.